SIGN UP
LOG IN
L
LXRX
Lexicon Pharmaceuticals Inc
0.75
0.00+0.60%After Hours: 0.7499 -0.00 -0.01%19:46 06/20 EDT
OPEN/PREV CLOSE0.7492/0.7455
TODAY RANGE0.7143-0.7623
VOL4.34M
MARKET CAP272.38M
52 WEEK RANGE0.2836-2.450
AVG VOL (3M)13.58M
% TURNOVER1.19%
TURNOVER--
P/E (TTM)-1.4580
% RANGE6.33%
EPS(TTM)-0.5144
P/E(FORWARD)-2.1739
P/B2.214
BVPS0.3388
DIVIDEND--
P/S8.72
BETA--
DIV YIELD0.00%
FREE FLOAT MKT CAP269.04M
SHARES OUTSTANDING363.18M
NEXT EARNINGS07/30-08/04
FREE FLOAT358.72M
LOT SIZE1
EX-DATE05/21/2015
News
Press Releases
Financial Reports
Profile
Simply Wall St·06/13 11:03
Revenues Not Telling The Story For Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) After Shares Rise 31%
NASDAQ·06/10 13:08
Alnylam Wins EC Nod for Label Expansion of Amvuttra for ATTR-CM
NASDAQ·06/06 15:52
KURA Stock Rises More Than 15% This Past Week: Here's Why
NASDAQ·06/06 15:35
TPST Stock Up on EMA's Orphan Drug Tag for Liver Cancer Therapy
NASDAQ·06/05 17:03
Zoetis Stock Rises 13% in a Month: Time to Add to Your Portfolio?
NASDAQ·06/05 16:55
Lyra Stock Soars 356% in a Week on Strong Rhinosinusitis Study Success
NASDAQ·06/04 16:17
JNJ's Combo Therapy Shows Strong Phase III Efficacy in Prostate Cancer
TipRanks·06/03 20:40
Lexicon Pharmaceuticals Holds Annual Stockholder Meeting
NASDAQ·06/03 15:14
Kymera Stock Gains on Positive Data on Investigational Dermatitis Drug
NASDAQ·06/03 13:43
Amgen's Imdelltra Cuts Lung Cancer Death Risk by 40% in Phase III
NASDAQ·06/02 14:53
MRK's ADC Drug Combo Shows Antitumor Activity in Lymphoma Study
NASDAQ·05/30 14:20
NTLA Stock Down as Patient Faces Adverse Event in Gene Therapy Study
NASDAQ·05/30 12:59
IMVT Q4 Loss Narrower Than Expected, Stock Up, Pipeline in Focus
NASDAQ·05/29 15:44
BMY's Opdivo SC Gets EU Nod for Multiple Solid Tumor Indications
Same Industry
Name/Symbol
Change%
Price
Risk Disclosure: The content of this page is not an investment advice and does not constitute any offer or solicitation to offer or recommendation of any investment product. It is for general purposes only and does not take into account your individual needs, investment objectives and specific financial circumstances. All investments involve risk and the past performance of securities, or financial products does not guarantee future results or returns. Keep in mind that while diversification may help spread risk it does not assure a profit, or protect against loss, in a down market. There is always the potential of losing money when you invest in securities, or other financial products. Investors should consider their investment objectives and risks carefully before investing. For more details, please refer to risk disclosure.
① During the campaign period, US stocks, US stocks short selling, US stock options, Hong Kong stocks, and A-shares trading will maintain at $0 commission, and no subscription/redemption fees for mutual fund transactions. $0 fee offer has a time limit, until further notice. For more information, please visit: https://www.webull.hk/pricing
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.
① During the campaign period, US stocks, US stocks short selling, US stock options, Hong Kong stocks, and A-shares trading will maintain at $0 commission, and no subscription/redemption fees for mutual fund transactions. $0 fee offer has a time limit, until further notice. For more information, please visit: https://www.webull.hk/pricing
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.
Language
English
©2025 Webull Securities Limited. All rights reserved.